A novel role for extracellular signal-regulated kinase 5 and myocyte enhancer factor 2 in medulloblastoma cell death

Cancer Research

Volumn 65, Issue 13, 2005, Pages 5683-5689

  Sturla, Lisa Marie ^a   Cowan, Christopher W ^a   Guenther, Lillian ^a   Castellino, Robert C ^b   Kim, John Y H ^b   Pomeroy, Scott L ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; MICROTUBULE ASSOCIATED PROTEIN 5; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MYOCYTE ENHANCER FACTOR 2; NEUROTROPHIN 3 RECEPTOR; PROTEIN PATCHED; SMALL INTERFERING RNA; TYROSINE KINASE C; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HETEROZYGOSITY; IMMUNOPRECIPITATION; MEDULLOBLASTOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CEREBELLAR NEOPLASMS; DNA-BINDING PROTEINS; ENZYME INHIBITORS; FLAVONOIDS; HUMANS; IMIDAZOLES; MEDULLOBLASTOMA; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 7; MYOGENIC REGULATORY FACTORS; NEUROTROPHIN 3; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PYRIDINES; RECEPTOR, TRKC; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 21344436391     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-2283     Document Type: Article

References (30)

1. Segal RA, Goumnerova LC, Kwon YK, Stiles CD, Pomeroy SL. Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. Proc Natl Acad Sci U S A 1994;91:12867-71.
2. Grotzer MA, Janss AJ, Fung K, et al. TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. J Clinical Oncology 2000;18:1027-35.
3. Kim JY, Sutton ME, Lu DJ, et al. Activation of neurotrophin-3 receptor TrkC induces apoptosis in medulloblastomas. Cancer Res 1999;59:711-9.
4. Kim JY, Nelson AL, Algon SA, et al. Medulloblastoma tumorigenesis diverges from cerebellar granule cell differentiation in patched heterozygous mice. Dev Biol 2003;263:50-66.
5. Cavanaugh JE, Ham J, Hetman M, Poser S, Yan C, Xia Z. Differential regulation of mitogen-activated protein kinases ERK1/2 and ERK5 by neurotrophins, neuronal activity, and cAMP in neurons. J Neurosci 2001;21:434-43.
6. Watson FL, Heerssen HM, Bhattacharyya A, Klesse L, Lin MZ, Segal RA. Neurotrophins use the Erk5 pathway to mediate a retrograde survival response. Nat Neurosci 2001;4:981-8.
7. Liu L, Cavanaugh JE, Wang Y, Sakagami H, Mao Z, Xia Z. ERK5 activation of MEF2-mediated gene expression plays a critical role in BDNF-promoted survival of developing but not mature cortical neurons. Proc Natl Acad Sci U S A 2003;100:8532-7.
8. Yang CC, Ornatsky OI, McDermott JC, Cruz TF, Prody CA. Interaction of myocyte enhancer factor 2 (MEF2) with a mitogen-activated protein kinase, ERK5/BMK1. Nucleic Acids Res 1998;26:4771-7.
9. Kato Y, Kravencho VV, Tapping RI, Han J, Ulevitch RJ, Lee JD. BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C. EMBO J 1997;16:7054-66.
10. Kasler HG, Victoria J, Duramad O, Winoto A. ERK5 is a novel type of mitogen-activated protein kinase containing a transcriptional activation domain. Mol Cell Biol 2000;20:8382-9.
11. Lin X, Shah S, Bulleit RF. The expression of MEF2 genes is implicated in CNS neuronal differentiation. Brain Res Mol Brain Res 1996;42:307-16.
12. Mao Z, Bonni A, Xia F, Nadal-Vicens M, Greenberg ME. Neuronal activity-dependent cell survival mediated by transcription factor MEF2. Science 1999;286:785-90.
13. Ikeshima H, Imai S, Shimoda K, Hata J, Takano J. Expression of a MADS box gene, MEF2D, in neurons of the mouse central nervous system: implication of its binary function in myogenic and neurogenic cell lineages. Neurosci Lett 1995;200:117-20.
14. Pomeroy SL, Tamayo P, Gaasenbeek M, et al. Prediction of central nervous system embryonal tumor outcome based on gene expression. Nature 2002;415:436-42.
15. Esparis-Ogando A, Diaz-Rodriguez E, Montero JC, Yuste L, Crespo P, Pandiella A. Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2. Mol Cell Biol 2002;22:270-85.
16. Weldon CB, Scandurro AB, Rolfe KW, et al. Identification of mitogen-activated protein kinase kinase as a chemoresistant pathway in MCF-7 cells by using gene expression microarray. Surgery 2002;132:293-301.
17. Mehta PB, Jenkins BL, McCarthy L, et al. MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion. Oncogene 2003;22:1381-9.
18. Goodrich LV, Milenkovic L, Higgins KM, Scott MP. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 1997;277:1109-13.
19. Han J, Jiang Y, Li Z, Kravchenko W, Ulevitch RJ. Activation of the transcription factor MEF2C by the MAPK p38 in inflammation. Nature 1997;386:296-9.
20. Molkentin JD, Firulli AB, Olsen EN. MEF2B is a potent transactivator expressed in early myogenic lineages. Mol Cell Biol 1996;16:3814-24.
21. Shalizi A, Lehtinen M, Gaudilliere B, et al. Characterization of a neurotrophin signaling mechanism that mediates neuron survival in a temporally specific pattern. J Neurosci 2003;23:7326-36.
22. 2+-induced release of the transcription factor MEF2. Science 1999;19:4323-31.
23. Linseman DA, Cornejo BJ, Le SS, et al. A myocyte enhancer factor 2D (MEF2D) kinase activated during neuronal apoptosis is a novel target inhibited by lithium. J Neurochem 2003;85:1488-99.
24. Han TH, Pruwes R. Regulatory role of MEF2D in serum induction of the c-jun promoter. Mol Cell Biol 1995;15:2907-15.
25. Shalizi A, Lehtinen M, Gaudilliere B, et al. Characterization of a neurotrophin signaling mechanism that mediates neuron survival in a temporally specific pattern. J Neurosci 2003;23:7326-36.
26. Duplan SM, Theoret Y, Kenigsberg RL. Anti-tumor activity of fibroblast growth factors (FGFs) for medulloblastoma may correlate with FGF receptor expression and tumor variant. Clin Cancer Res 2002;8:246-57.
27. Miyazawa K, Himi T, Garcia V, Yamagashi H, Sato S, Ishizaki Y. A role for p27/Kip1 in the control of cerebellar granule cell precursor proliferation. J Neurosci 2000;20:5756-63.
28. Askew DS, Ashmun RA, Simmons BC, Cleveland JL. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 1991;6:1915-22.
29. Hoffman B, Liebermann DA. The proto-oncogene c-myc and apoptosis. Oncogene 1998;17:3351-7.
30. Chou TT, Trojanowski JQ, et al. A novel apoptotic pathway induced by nerve growth factor-mediated TrkA activation in medulloblastoma. J Biol Chem 2000;275:565-70.